Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


LSP co-leads Series A financing round of Skyline Diagnostics


Amsterdam, October 5th, 2007
LSP (Life Sciences Partners) announced today the closure of the Series A financing round of Skyline Diagnostics B.V. The round was co-led by the Erasmus MC Biomedical Fund.

Skyline Diagnostics is a spin-off company from the Erasmus University Medical Center in Rotterdam. The company develops and commercializes diagnostic tools for cancer using microarray technology. The diagnostic device furnishes a genomic fingerprint of the tumor that permits a precise diagnosis and a predictive assessment of the individual’s prognosis. The company currently has three products in its development pipeline: biochips for acute myeloid leukemia, brain tumors and myeloma (Kahler’s disease).

Dr. Henk Viëtor, CEO of Skyline Diagnostics: “We very pleased to have two experienced venture capital investors like LSP and the Erasmus MC Biomedical Fund investing in our company. This will enable Skyline to fulfill its ambitions to take the next essential steps in bringing its first product, the AML Biochip, to the market. Acute myeloid leukemia (AML) is the most common form of leukemia. This product will provide clinicians new insights in the prognosis and course of the disease.”

“We are excited to be making this investment in Skyline Diagnostics, which we believe is one of the most promising companies in its field today” says Tom Schwarz, partner at the Erasmus MC Biomedical Fund. “The combination of world class science, experienced management and strong financial backing will allow the company to successfully develop and market its diagnostic products. I am personally looking forward to working closely with the management team as a new member of the company’s Supervisory Board.”

Dr. John de Koning, investment manager at LSP and member of Skyline Diagnostics’ Supervisory Board: “Skyline Diagnostics is a frontrunner in implementing microarray diagnostics in clinical practice. Building on the company’s expertise and broad scientific and clinical network, we expect Skyline Diagnostics to be in an excellent position to successfully bring its products to the market, creating long-term value. We are delighted to be able to support the Company and its management team in attaining this goal.” LSP will invest from its Seed Fund that is supported by TechnoPartner, a Dutch agency of the Department of Economic Affairs.

About Skyline Diagnostics (www.skyline-diagnostics.nl)
Skyline Diagnostics develops and commercializes diagnostic products for cancer using gene expression profiling. This technology enables scientists to study the activity of nearly the complete human genome in one single experiment and can provide the clinician new insight in the development and prognosis of disease and the response to treatment. The company collaborates closely with several departments of the Erasmus MC to ensure disease expertise and new diagnostic signatures. Skyline was founded in 2005 by the inventors (Departments of Hematology and Bio-informatics) of the gene expression profile for AML (including Prof. dr. B. Löwenberg, CSO of the company) and dr. Henk Viëtor (CEO). Skyline has close collaborations with several academic and industrial partners including Affymetrix (Santa Clara, USA) and holds a Powered by AffymetrixTM (PbA) licensing deal for several cancer indications. In 2007, Skyline received the BioBusiness “Start-up of the Year Award”. The company aims to launch the first product (the AML Biochip) in 2008.

About LSP (www.lspvc.com)
LSP (Life Sciences Partners) is a leading independent European venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With EUR 400 million under management and offices in A


Publisher Contact Information:

Life Sciences Partners (LSP)
+ 31 (0) 20 664 5500
mkleijwegt@lspvc.com

Company profile of Life Sciences Partners (LSP)
Past press releases of Life Sciences Partners (LSP).

Data


26,227
Tech investments
From our Online Data Service
16,943
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.